Krystal Biotech (KRYS) and Its Peers Financial Survey

Krystal Biotech (NASDAQ:KRYS) is one of 844 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Krystal Biotech to related companies based on the strength of its dividends, valuation, institutional ownership, risk, earnings, profitability and analyst recommendations.

Insider and Institutional Ownership

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 13.1% of Krystal Biotech shares are held by company insiders. Comparatively, 12.9% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Krystal Biotech and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	54.82%	19.34%	17.65%
Krystal Biotech Competitors	-9,054.47%	-198.89%	-30.64%

Earnings & Valuation

This table compares Krystal Biotech and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Krystal Biotech	$389.13 million	$204.83 million	38.22
Krystal Biotech Competitors	$743.53 million	$13.62 million	-10.02

Krystal Biotech’s competitors have higher revenue, but lower earnings than Krystal Biotech. Krystal Biotech is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of current recommendations for Krystal Biotech and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	1	1	10	2	2.93
Krystal Biotech Competitors	9782	15052	45296	1571	2.54

Krystal Biotech presently has a consensus target price of $375.00, suggesting a potential upside of 22.94%. As a group, “Biotechnology” companies have a potential upside of 99.31%. Given Krystal Biotech’s competitors higher probable upside, analysts clearly believe Krystal Biotech has less favorable growth aspects than its competitors.

Risk & Volatility

Krystal Biotech has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500. Comparatively, Krystal Biotech’s competitors have a beta of 1.12, suggesting that their average share price is 12% more volatile than the S&P 500.

Summary

Krystal Biotech beats its competitors on 10 of the 13 factors compared.

Krystal Biotech Company Profile

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.